Advertisement

Topics

Eli Lilly and Nektar Develop Autoimmune Therapy

22:21 EDT 30 Jul 2017 | CHEManager

US pharma companies Eli Lilly and Nektar Therapeutics have signed an agreement to jointly develop the latter’s novel immunotherapy, NKTR-358, which could potentially treat a number of autoimmune and other chronic inflammatory conditions. The collaboration would be worth as much as $400 million for Nektar.

Original Article: Eli Lilly and Nektar Develop Autoimmune Therapy

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly and Nektar Develop Autoimmune Therapy"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...